LMP 420

Drug Profile

LMP 420

Alternative Names: LMP-420

Latest Information Update: 01 Mar 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of North Carolina at Chapel Hill
  • Developer LeukoMed
  • Class Antirheumatics; Inorganic boron compounds; Purines
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Crohn's disease; Rheumatoid arthritis

Most Recent Events

  • 17 May 2007 This programme is still in active development
  • 27 Sep 2002 LMP 420 is available for licensing in the US and Europe (http://www.leukomed.com)
  • 27 Sep 2002 Preclinical trials in Crohn's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top